Vistagen Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · South San Francisco, CA
VTGN chart
What traders are saying about $VTGN
Latest postsVistagen Therapeutics, Inc. news
- Vistagen Therapeutics, Inc. Estimates – BIVA:VTGN
TradingView ·
- Vistagen brings in GATC Health's predictive AI to design next trials of its neuroscience pipeline
Dealroom ·
- Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
Yahoo Finance ·
- Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight
Yahoo Finance ·
- 2 Falling Stocks Call Traders Are Targeting Today
Yahoo Finance ·
- SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
Yahoo Finance ·
- Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder
investorshub.advfn.com ·
- Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
Yahoo Finance ·
- Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Yahoo Finance ·
- Vistagen to Present at Psych Congress 2026
Yahoo Finance ·
- Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Yahoo Finance ·
- Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Yahoo Finance ·
Vistagen Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | -$227,000 |
| Net income | -$69.7M | -$51.4M | -$29.4M | -$59.2M |
| Diluted EPS | $-1.83 | $-1.67 | $-1.52 | $-8.51 |
| Total assets (year end) | $65.1M | $92.3M | $131.1M | $29.7M |
| Cash and equivalents (year end) | $47.4M | $74.7M | $126.6M | $25.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Vistagen Therapeutics, Inc.
- Ticker
- VTGN (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- South San Francisco, CA
- Incorporated in
- NV
- Fiscal year end
- March 31
- SEC CIK
- 1411685
- Former names
- Excaliber Enterprises, Ltd.
Frequently asked questions
What exchange is Vistagen Therapeutics, Inc. listed on?
Vistagen Therapeutics, Inc. trades on the Nasdaq under the ticker symbol VTGN.
What industry is Vistagen Therapeutics, Inc. in?
Vistagen Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Vistagen Therapeutics, Inc. headquartered?
Vistagen Therapeutics, Inc.'s business address on file with the SEC is in South San Francisco, CA.
When does Vistagen Therapeutics, Inc.'s fiscal year end?
Vistagen Therapeutics, Inc.'s fiscal year ends on March 31.
How much revenue did Vistagen Therapeutics, Inc. report?
Vistagen Therapeutics, Inc. reported -$227,000 in revenue for calendar year 2022, according to its SEC filings.